ABSTRACT Cold atmospheric plasma (CAP) has potential as a new cancer treatment tool due to its room temperature biocompatibility and possible cancer cell selectivity with low side effects. This review examines the current research stage of CAP therapy for Prostate Cancer (PCa) treatment with a focus on CAP device standardization and CAP therapy clinical translation. The current CAP preclinical data is explored through the lens of PCa cellular response, PCa cells selectivity, CAP treatment type and CAP combination therapies. Finally, building on the current preclinical data, this review proposes the potential clinical application methods of CAP at different PCa stages to promote CAP therapy into clinical use.
Zhang et al. (Thu,) studied this question.